Siemens healthcare diagnostics is investigating.
The interpretation of results section of the instructions for use states: "results of this assay should always be interpreted in conjunction with patient's medical history, clinical presentation and other findings.
" the limitations section of the instructions for use states: "warning do not use the advia centaur ca 19-9 assay as a screening test or for diagnosis.
Do not predict disease recurrence solely on levels of advia centaur ca 19-9.
Normal levels of advia centaur ca 19-9 do not always preclude the presence of disease.
" note: do not interpret serum levels of ca 19-9 as absolute evidence of the presence or the absence of malignant disease.
Before treatment, patients with confirmed gi carcinoma frequently have levels of ca 19-9 within the range observed in healthy individuals.
Additionally, elevated levels of ca19-9 can be observed in patients with nonmalignant diseases.
Measurements of ca19-9 should always be used in conjunction with other diagnostic procedures, including information from the patient's clinical evaluation.
The concentration of ca 19-9 in a given specimen determined with assays from different manufacturers can vary because of differences in assay methods, calibration, and reagent specificity.
Ca 19-9 determined with different manufacturers' assays will vary depending on the method of standardization and antibody specificity.
Therefore, it is important to use assay specific values to evaluate quality control results.
" mdr 1219913-2019-00266 was filed for the same event for the advia centaur xpt ca19-9 repeat result.
|